(Q38444650)

3 September 2017

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage (English)

1 reference

3 September 2017

0 references

0 references

1 reference

10

1 reference

3 September 2017

Maria A Rocca

2

0 references

Massimo Filippi

object named as

Massimo Filippi

1

0 references

Nicola De Stefano

object named as

Nicola De Stefano

4

0 references

Ludwig Kappos

6

object named as

Ludwig Kappos

1 reference

3 September 2017

9

Giancarlo Comi

1 reference

3 September 2017

3

Elisabetta Pagani

1 reference

3 September 2017

7

Xavier Montalban

1 reference

3 September 2017

Douglas Jeffery

5

1 reference

PubMed ID

24029546

3 September 2017

Alexei N Boyko

8

1 reference

PubMed ID

24029546

3 September 2017

language of work or name

English

0 references

publication date

12 September 2013

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

3 September 2017

1 reference

3 September 2017

85

1 reference

3 September 2017

8

1 reference

3 September 2017

851-858

1 reference

Placebo-controlled trial of oral laquinimod for multiple sclerosis

3 September 2017

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

The measurement and clinical relevance of brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Association between pathological and MRI findings in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Thalamic damage and long-term progression of disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Gray matter atrophy in multiple sclerosis: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Magnetic resonance spectroscopy: imaging axonal damage in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Automatic quantitation of localized in vivo 1H spectra with LCModel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Localization of grey matter atrophy in early RRMS : A longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306132

21 January 2018

Identifiers

DOI

10.1136/JNNP-2013-306132

1 reference

3 September 2017

1 reference

PubMed ID

24029546